More Marketing Wars: Lantus vs. Levemir
Another larger-than-life Diabetes Marketing War, this time without the romantic names:
A while back I wrote a post introducing the first-ever competitor to Sanofi-Aventis’ long-acting insulin, Lantus. The new product is called Levemir, from Novo Nordisk.
What I missed more recently was that things turned ugly back in March. Sanofi filed suit against Novo Nordisk in a New Jersey U.S. District Court claiming that Novo was falsely promoting their drug as effective for 24 hours,…